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Introduction {#sec1}
============

Pluripotent cells are present in the human embryo for around 10 days, from emergence in the blastocyst until lineage commitment during gastrulation ([@bib21]). *In vitro*, two classes of human pluripotent stem cell (hPSC) have been described. Conventional hPSCs, derived from inner cell mass (ICM) explants ([@bib17], [@bib33]) or generated by somatic cell reprogramming (induced pluripotent stem cells \[(iPSCs\]) ([@bib29]), share characteristics with late post-implantation gastrulating epiblast ([@bib15]). Propagation of stem cells resembling naive emergent epiblast has been reported more recently ([@bib8], [@bib30], [@bib32]). Naive hPSCs are generated by conversion from conventional PSCs, a process termed resetting. In addition, embryonic stem cells (ESCs) with naive features have been derived directly from dissociated ICM cells from day-6 human blastocysts ([@bib9]). Naive-type hPSCs have also been obtained following somatic cell reprogramming ([@bib11], [@bib13]). The availability of naive and conventional hPSCs provides two complementary systems for modeling early human development. In particular, the global relationship of naive hPSCs to pre-implantation embryo epiblast ([@bib15], [@bib27]) provides an opportunity to study and dissect the progression of pluripotency over a time window of human embryogenesis that is inaccessible *in utero*.

Current conditions employed to generate naive hPSCs show variation in efficiency, especially when applied across different cell lines ([@bib8]). Reliable cell-surface markers would aid identification and establishment of naive hPSCs and facilitate optimization of culture conditions and procedures. To date several surface markers have been reported that may distinguish naive from conventional hPSCs. Some of these are expressed by conventional hPSCs and not by naive hPSCs ([@bib16], [@bib19], [@bib24]) while others show only differences in level between the two PSC types ([@bib13], [@bib16]). On the other hand, markers claimed to be specific for naive PSCs ([@bib3]) show either no expression or broad expression in early human embryos, challenging their relevance for identification specifically of the naive pluripotent phenotype.

Here we present Sushi Containing Domain 2 (SUSD2) ([@bib28]) as a robust cell-surface marker of naive pluripotency in the human embryo and hPSCs *in vitro*. We identified high enrichment of *SUSD2* in naive pre-implantation epiblast through analysis of differential gene expression in human embryos. We evaluated SUSD2 protein expression by antibody staining of human blastocysts and of naive and conventional PSC cultures. Finally, we investigated the applicability of SUSD2 live cell staining and flow cytometry during resetting and reprogramming to naive PSC status.

Results {#sec2}
=======

Sushi Containing Domain 2 Is a Marker for Naive Pluripotency {#sec2.1}
------------------------------------------------------------

To identify candidate markers for human naive pluripotent cells we scanned integrated single-cell RNA-sequencing datasets from early human embryos ([@bib27]) for transmembrane proteins differentially expressed in the pre-implantation epiblast. We observed that Sushi Containing Domain 2 (*SUSD2*) is highly enriched in the ICM at embryonic day (E) 5 and has a mean level in epiblast cells at E6--7 that is 8-fold higher than in primitive endoderm or trophectoderm (p \< 0.005) ([Figure 1](#fig1){ref-type="fig"}A). In contrast, other recently reported surface markers for naive cells are either not detectable or not specific to epiblast ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1SUSD2 Is Expressed by Human Naive Pluripotent Cells in the Embryo and in Culture(A) *SUSD2* transcript levels in human pre-implantation embryos at different stages and lineages, extracted from integrated single-cell RNA-sequencing data ([@bib27]).(B) Immunostaining for KLF17, GATA4, and SUSD2 in the E7 human blastocyst. Scale bars, 50 μm.(C) *SUSD2* transcript levels in naive and conventional hPSCs ([@bib27]).(D) Flow-cytometry analysis of SUSD2 in conventional and naive cells.(E) Images of bright-field and SUSD2 immunostaining using a SUSD2-PE antibody. Scale bar, 50 μm.(F) Immunostaining for SUSD2, TFCP2L1, and KLF17 in conventional and naive (cR-S6 and HNES1) cells. Scale bars, 100 μm.(G) Flow-cytometry analysis of SUSD2 expression during capacitation of cR-S6 and HNES1 cells.(H) *SUSD2* transcript levels in *Macaca fascicularis* embryos ([@bib15]). cMOR, compacted morula; eICM, early inner cell mass; TE, trophectoderm; Epi, epiblast; PrE, primitive endoderm.See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.

SUSD2 is a type I membrane protein with a large extracellular domain ([@bib28]) against which there are several commercial antibodies ([@bib25]). We therefore examined whether SUSD2 protein expression reflects transcript distribution. We immunostained E7 human embryos using a monoclonal antibody. Intense cell-surface staining was observed on a subset of cells within the ICM ([Figures 1](#fig1){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). These SUSD2 positive cells co-express the transcription factor KLF17, denoting human naive epiblast identity ([@bib1], [@bib9], [@bib27]). In contrast, SUSD2 staining was faint in trophectoderm cells and absent in GATA4-positive hypoblast cells.

We then inspected publicly available hPSC transcriptome data ([@bib6], [@bib9], [@bib8], [@bib27], [@bib30], [@bib32], [@bib35], [@bib36]). We found that *SUSD2* transcript levels are appreciable only in cells cultured in either t2iLGö or 5iLAF medium, which satisfy stringent criteria for naive pluripotent features ([@bib4], [@bib10], [@bib15], [@bib27], [@bib30], [@bib32], [@bib31]) ([Figure 1](#fig1){ref-type="fig"}C). *SUSD2* mRNA is very low or absent in conventional or other hPSCs, including cultures in NHSM ([@bib6]) and so-called extended pluripotent stem cells ([@bib36]). These observations indicate that SUSD2 expression may be a distinguishing marker for naive hPSCs.

We therefore investigated the utility of SUSD2 antibodies for discriminating hPSC phenotypes. Flow-cytometry analysis showed no detectable expression in conventional hPSC ([Figure 1](#fig1){ref-type="fig"}D). In contrast, SUSD2 was expressed unimodally at high levels in embryo-derived HNES1 naive hPSCs ([@bib9]). This was the case both for cultures in the original t2iLGö formulation ([@bib30]), and in a modified version, PXGL ([@bib8]), including the tankyrase inhibitor XAV939 and omitting GSK3 inhibition (for details see [Experimental Procedures](#sec4){ref-type="sec"}) ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B). SUSD2 was also highly expressed in chemically reset (cR) naive hPSCs in PXGL medium ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Comparative flow-cytometry analysis with other reported naive cell-surface markers ([@bib3]) revealed that only CD75 exhibits a similar profile to SUSD2, while other markers did not effectively discriminate naive from conventional hPSCs, or were weakly expressed ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

We noted strong *in situ* cell-surface staining of naive hPSCs using a conjugated SUSD2 monoclonal antibody ([Figure 1](#fig1){ref-type="fig"}E). Importantly, live staining did not perturb cell viability or morphology, and naive cells could subsequently be expanded without consequence. With the exception of heterogeneous staining for CD7, *in situ* reactivity was not detected using conjugated antibodies for CD75 or other reported naive markers ([@bib3]) ([Figure S2](#mmc1){ref-type="supplementary-material"}C). We also evaluated SUSD2 immunostaining after paraformaldehyde fixation ([Figure 1](#fig1){ref-type="fig"}F). We detected no signal on conventional hPSCs but intense surface staining of naive cells. SUSD2-immunopositive cells co-expressed the naive transcription factor TFCP2L1 and the primate-specific naive transcription factor KLF17 ([@bib1], [@bib9], [@bib30]).

To initiate multi-lineage differentiation, naive hPSCs must transition to a state approaching conventional hPSCs, a process we have termed capacitation ([@bib26]). Capacitation is achieved by withdrawal of t2iLGö or PXGL and culture for 8--10 days in N2B27 medium supplemented with XAV939 ([@bib22]) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). SUSD2 expression is progressively downregulated during capacitation and is absent by day 8 ([Figure 1](#fig1){ref-type="fig"}G). Change in cell state after capacitation is confirmed by loss of colony-forming ability in naive cell medium ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We have shown elsewhere that naive hPSC capacitation reflects *in vivo* progression of the epiblast from ICM to late post-implantation in the embryo of the non-human primate *Macaca fascicularis* ([@bib22]). We examined the *Macaca* dataset ([@bib15]) and found *SUSD2* mRNA is present in pre-implantation epiblast but not at post-implantation stages ([Figure 1](#fig1){ref-type="fig"}H). Thus, SUSD2 expression in hPSCs is closely linked to naive status both in cultured stem cells and in the primate embryo.

SUSD2 Identifies Naive hPSCs after Chemical Resetting {#sec2.2}
-----------------------------------------------------

Conventional hPSCs can be reset to naive status by short-term exposure to the histone deacetylase inhibitor valproic acid followed by culture in naive medium ([@bib8]). Naive hPSCs are then enriched by continuous passaging. We investigated whether SUSD2 could be utilized to identify naive cells upon chemical resetting ([Figure 2](#fig2){ref-type="fig"}A). We used Shef6 (S6)-EOS and H9-EOS hPSCs in which the *PB-EOS-GFP* transgene provides a reporter of naive status ([@bib8], [@bib30]). Live cell imaging on day 10 of resetting revealed co-expression of EOS-GFP and SUSD2 in emerging domed naive-type colonies ([Figure 2](#fig2){ref-type="fig"}B).Figure 2SUSD2 Identifies and Purifies Reset Naive hPSCs(A) Schematic of the chemical resetting protocol. HDACi, histone deacetylase inhibitor.(B) Images of cultures at day 10 of resetting. Scale bar, 50 μm.(C and D) Flow-cytometry analysis of SUSD2 and CD24 expression in conventional and naive hPSCs (C) and during resetting (D).(E) Flow-cytometry analysis of GFP and SSEA4 on SUSD2^+^CD24^−^ cells at day 14 of resetting.(F) Immunostaining for SUSD2, NANOG, and KLF17 at day 14 of resetting. Scale bar, 100 μm.(G) qRT-PCR analysis of sorted SUSD2^+^CD24^−^ and SUSD2^−^CD24^+^ cells at day 10 and day 14 of resetting. Error bars indicate SD of three independent experiments.(H) Flow cytometry sort plot at day 14 of resetting.(I) Flow-cytometry analysis of SUSD2 and CD24 expression on cell populations sorted in (H), 5 days after sorting. SUSD2^+^, SUSD2^+^CD24^−^; SUSD2^−^, SUSD2^−^CD24^+^.(J) Bright-field and GFP images of cell populations sorted in (H) at passages 1 and 5 after sorting. Scale bar, 50 μm.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We performed flow-cytometry analyses for SUSD2 along with the conventional hPSC marker, CD24 ([@bib24]). SUSD2^+^CD24^−^ and SUSD2^−^CD24^+^ cell-surface phenotypes unambiguously distinguish naive from conventional hPSCs ([Figure 2](#fig2){ref-type="fig"}C). At the start of resetting, all hPSCs are SUSD2^−^CD24^+^. By day 10, a substantial proportion (20%--30%) of cells are SUSD2^+^ and either CD24 low or CD24 negative ([Figure 2](#fig2){ref-type="fig"}D). By day 14, most SUSD2^+^ cells are negative for CD24 and also for SSEA4 ([Figures 2](#fig2){ref-type="fig"}D and 2E), another marker of conventional PSCs that is absent on naive hPSCs ([@bib19]). The vast majority of SUSD2^+^ (\>95%) cells at this stage express EOS-GFP ([Figure 2](#fig2){ref-type="fig"}E).

Immunostaining of S6-EOS and H9-EOS cultures at day 14 of resetting showed co-expression of SUSD2 with transcription factors KLF17 and NANOG ([Figure 2](#fig2){ref-type="fig"}F). SUSD2-negative cells did not express either of these factors. We purified SUSD2^+^CD24^−^ populations at days 10 and 14 for further analysis of marker expression by qRT-PCR. Expression of naive markers *KLF4*, *KLF17*, *TFCP2L1*, *DPPA3*, and *DPPA5* was restricted to SUSD2^+^CD24^−^ cells and absent or very low in the SUSD2^−^CD24^+^ fraction ([Figure 2](#fig2){ref-type="fig"}G).

Together, these observations indicate that SUSD2 staining in combination with absence of CD24 or SSEA4 identifies reset naive PSCs. We therefore investigated whether SUSD2 antibody staining could be utilized to purify naive PSCs from resetting cultures. We fractionated SUSD2^+^CD24^−^ and SUSD2^−^CD24^+^ populations by flow cytometry on day 14 of resetting and plated them in PXGL ([Figures 2](#fig2){ref-type="fig"}H and [S4](#mmc1){ref-type="supplementary-material"}A). Analysis 5 days later showed that the great majority of cells retained the cell-surface phenotype from sorting ([Figures 2](#fig2){ref-type="fig"}I and [S4](#mmc1){ref-type="supplementary-material"}A). Consistent with the flow profile, SUSD2^+^CD24^−^ sorted cells generated numerous EOS-GFP^+^ dome-shaped colonies with few if any other colony types apparent. In contrast, SUSD2^−^CD24^+^ cells yielded predominantly heterogeneously differentiated cells that were EOS-GFP^−^, with only the occasional GFP^+^ domed colony ([Figures 2](#fig2){ref-type="fig"}J and [S4](#mmc1){ref-type="supplementary-material"}A).

The SUSD2^+^CD24^−^ sorted cultures retained morphological naive features and maintained EOS-GFP expression upon passaging ([Figures 2](#fig2){ref-type="fig"}J and [S4](#mmc1){ref-type="supplementary-material"}A). qRT-PCR analysis at passage 1 (P1) and P3 after sorting showed that expression of naive markers *KLF4*, *KLF17*, *TFCP2L1*, and *DPPA5* was sustained in SUSD2^+^CD24^−^-derived cells but remained negligible in the SUSD2^−^CD24^+^ derivatives ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Flow-cytometry analysis of SUSD2^+^CD24^−^ sorted cells at later passages showed maintenance of purified SUSD2^+^ cells (\>98%). In contrast, parallel unsorted reset cultures retained subpopulations of both SUSD2^lo^CD24^+^ and SUSD2^−^CD24^+^ cells, in addition to the major SUSD2^+^CD24^−^ population ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

SUSD2 Sorting Facilitates Establishment of Naive hPSC Cultures {#sec2.3}
--------------------------------------------------------------

The efficiency of chemical or transgene-driven resetting from conventional to naive hPSCs is variable, and extended passaging may be required to establish homogeneous cultures ([@bib8], [@bib30]). We utilized SUSD2 to monitor efficiency and purify naive cells during resetting of diverse human ESC and iPSC lines. We applied the chemical resetting protocol to two conventional human ESCs, H1 and H7 ([@bib33]) and two iPSCs, MeCP2-clone17 and NCRM-2. Flow-cytometry analysis of resetting cultures at day 10, day 14, P1, and P3 revealed that SUSD2^+^CD24^−^ populations appeared with different frequencies and kinetics for the individual cell lines ([Figure 3](#fig3){ref-type="fig"}A). Resetting efficiency, quantified by SUSD2^+^CD24^−^ cell fraction at P3, ranged from 22% to 98% ([Figure 3](#fig3){ref-type="fig"}A). The identity of SUSD2^+^ cells was evaluated by qRT-PCR analysis whereby, as shown previously, expression of naive markers *KLF4*, *KLF17*, *TFCP2L1*, and *DPPA5* was restricted to SUSD2^+^CD24^−^ cells ([Figure 3](#fig3){ref-type="fig"}B).Figure 3SUSD2 Identifies Reset Naive hPSCs upon Resetting of Multiple Cell Lines(A) Flow-cytometry analysis of SUSD2 and CD24 expression during resetting of two human ESC lines (H1 and H7) and two iPSC lines (MECP2-clone17 and NCRM-2).(B) qRT-PCR analysis of marker expression in sorted SUSD2^+^CD24^−^ and SUSD2^−^CD24^+^ cells at passage 3 (P3). Note that no SUSD2^−^CD24^+^ population is evident for the cR-H1 line. *DPPA5* expression is shown at 0.5× actual expression. Error bars indicate SD of two independent experiments.(C) Flow-cytometry analysis of SUSD2 and CD24 expression and bright-field images of reset cultures at P5. Top row: unsorted reset cultures; bottom row: cultures sorted for SUSD2^+^CD24^−^ at P3. Scale bar, 50 μm.(D) Immunostaining for SUSD2, NANOG, and KLF17 at P6 for cultures that were sorted for SUSD2^+^CD24^−^ at P3. Scale bar, 100 μm.(E) Immunostaining for NANOG, MECP2, and SUSD2 on reset (P6) and parental MECP2-clone17 cells. Scale bar, 100 μm.

We purified SUSD2^+^CD24^−^ cells by flow cytometry at P3. Replating resulted in uniform cultures of naive-type colonies. In contrast, unsorted cultures displayed persisting heterogeneity ([Figure 3](#fig3){ref-type="fig"}C). Immunostaining showed co-expression of SUSD2, NANOG, and KLF17 throughout naive cultures after sorting ([Figure 3](#fig3){ref-type="fig"}D). Post-sort cultures were expanded for ten passages in PXGL and retained domed colony morphology.

MeCP2-clone17 cells are heterozygous for a loss-of-function mutation in the X-linked gene *MECP2* ([@bib12], [@bib23]). MeCP2 protein is not expressed in conventional MeCP2-clone17 cells because the wild-type allele is on the silent X chromosome. Upon resetting, the silent X is expected to be reactivated ([@bib8]). Consistent with this, immunostaining revealed co-expression of MeCP2 with SUSD2 in sorted reset cultures, providing further evidence of naive status ([Figure 3](#fig3){ref-type="fig"}E).

These findings demonstrate the utility of SUSD2^+^ staining during chemical resetting, bypassing the requirement for a transgenic reporter or prolonged passaging to establish homogeneous naive cultures from different starting hPSC lines, even when the initial frequency of resetting is poor.

SUSD2 Identifies Emerging Naive hPSCs during Somatic Cell Reprogramming {#sec2.4}
-----------------------------------------------------------------------

Naive hPSCs can be generated from somatic cells by molecular reprogramming ([@bib7], [@bib11], [@bib13]). We used Sendai viral (SeV) vectors to reprogram human diploid fibroblasts ([Figure 4](#fig4){ref-type="fig"}A) ([@bib5]). One week after transfection we observed small patches of cells undergoing mesenchymal-to-epithelial transition. On day 8 culture medium was exchanged to PXGL supplemented with ROCK inhibitor Y-27632 ([Figure 4](#fig4){ref-type="fig"}A). Six days following transfer to PXGL, SUSD2-positive cells emerged ([Figure 4](#fig4){ref-type="fig"}B). By 10 days multiple SUSD2-positive domed colonies were apparent. Flow-cytometry analysis showed that the majority of cells in the culture at day 10 are SUSD2^+^ and CD24^−^ ([Figure 4](#fig4){ref-type="fig"}C). These cultures can be bulk passaged and further propagated to establish naive iPSCs.Figure 4SUSD2 Identifies Naive hPSCs during Somatic Cell Reprogramming(A) Schematic of the reprogramming protocol.(B--D) Sendai vector reprogramming of human dermal fibroblasts. (B) Images of bright-field and SUSD2 live staining. Scale bar, 50 μm. (C) Flow-cytometry analysis of SUSD2 and CD24 expression. (D) Immunostaining for SUSD2, NANOG, and KLF17. Scale bar, 50 μm.(E) qRT-PCR analysis of markers on sorted SUSD2^+^CD24^−^ at day 8 + 14 for Sendai vector- and episomal-mediated reprogramming, and on established naive hPSCs. Bars indicate the SD of two independent experiments.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We also examined SUSD2 expression during reprogramming using episomal *pCXLE* vectors ([@bib18]) and found that positive cells appeared with similar kinetics as in SeV reprogramming. However, the episomal system produced more heterogeneous cultures ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We therefore used EpCAM to exclude any mesenchymal cells that may express SUSD2 ([@bib25]). Flow-cytometry analysis identified an EpCAM^+^SUSD2^+^CD24^−^ population 7 days after transfer to PXGL that increased to 13% of the culture by day 14 ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Immunostaining of reprogrammed cultures on day 14 showed co-expression of SUSD2 with KLF17 in both SeV and episomal systems ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}F). qRT-PCR analysis of isolated SUSD2^+^CD24^−^ populations in both cases confirmed expression of naive pluripotency markers at similar levels to embryo-derived HNES1 naive hPSCs ([Figure 4](#fig4){ref-type="fig"}E). These results demonstrate that SUSD2 marks emerging naive iPSCs during somatic cell reprogramming.

Discussion {#sec3}
==========

SUSD2 is a type I membrane protein of unknown function ([@bib28]). It is expressed by various cell types in development and adulthood, and has been used to fractionate both pancreatic and mesenchymal progenitors ([@bib14], [@bib20], [@bib25]). However, it has not previously been associated with pluripotent cells, *in vivo* or *in vitro*.

Our findings reveal that SUSD2 is highly enriched in naive epiblast in the human blastocyst and uniformly expressed on the cell surface of naive hPSCs, but is absent from other hPSCs. SUSD2 is lost as naive hPSCs transition toward differentiation, consistent with transcriptional downregulation observed in the post-implantation cynomolgus embryo. Future investigation will determine whether the restricted expression of SUSD2 has functional consequence for naive pluripotency.

SUSD2 antibody binding provides non-invasive labeling for live cell imaging and flow-cytometric cell sorting with no evident deleterious effects. SUSD2 strongly stains naive hPSCs *in situ* and allows unambiguous discrimination of naive from conventional hPSCs by flow cytometry. Several candidate markers for distinguishing naive hPSCs have recently been reported ([@bib3], [@bib13], [@bib16], [@bib19], [@bib24]) and reviewed ([@bib34]). Among these, F11R is highly expressed by naive hPSCs ([@bib16]) but is also present at substantial levels on conventional cells ([@bib13]) ([Figure S1](#mmc1){ref-type="supplementary-material"}). Of the other markers reported for naive hPSCs ([@bib3]), CD75, CD77, and CD130 display broad mRNA expression and antibody staining in E6 embryos while CD7 mRNA is not detected in the human embryo. CD7 and CD77 do not resolve naive hPSCs from conventional hPSCs by flow cytometry, while CD130 expression is weak. CD75, CD77, and CD130 antibodies did not stain naive hPSCs *in situ* while anti-CD7 stained heterogeneously. In contrast, SUSD2 decisively labels naive hPSCs, and provides assurance of embryo lineage and hPSC classification not offered by current markers.

Live cell staining or flow-cytometry analysis for SUSD2 provides simple and reliable means to routinely monitor hPSC culture status. This is useful because culture conditions for naive hPSCs have yet to be fully optimized, and cells can become heterogeneous during maintenance. SUSD2 is particularly valuable in facilitating the establishment of naive hPSCs by resetting or reprogramming procedures. Current protocols are relatively inefficient, and extended passaging may be required to enrich for the naive phenotype. Sorting for SUSD2^+^ and against a conventional hPSC marker such as CD24 or SSEA4 allows efficient purification from mixed resetting cultures and, thus, more rapid establishment of naive PSC lines.

In summary, our findings illustrate the utility of SUSD2 antibody staining for classification, quantification, and isolation of naive hPSCs. We envisage that SUSD2 staining will be a useful tool for optimization of resetting and reprogramming conditions. It will also be of future interest to determine whether SUSD2 plays a significant biological role in naive pluripotent cells.

Experimental Procedures {#sec4}
=======================

Ethics Statement {#sec4.1}
----------------

Human embryo research was licensed by the UK Human Fertilization and Embryology Authority under research licence RO178. Supernumerary embryos were donated from *in vitro* fertilization programs with informed consent.

Cell Culture {#sec4.2}
------------

Conventional hPSC cultures were propagated on Geltrex (growth factor-reduced, Thermo Fisher, A1413302) in Essential 8 (E8) medium made in-house ([@bib2]). hESC lines were Shef6, S6-EOS, H9-EOS, H1, and H7; human iPSCs were NCRM-2 (NINDS Repository) and MECP2-clone17 ([@bib23]) gifted by Kathrin Plath. Chemically reset (cR) or embryo-derived (HNES1) naive PSCs were propagated in N2B27 with PXGL. Cells were cultured in 5% O~2~, 7% CO~2~ in a humidified incubator at 37°C and passaged by dissociation with Accutase (Thermo Fisher Scientific, A1110501) every 3--5 days. Cell lines were confirmed free of mycoplasma contamination by periodic in-house PCR assay. For capacitation, cells were passaged once without feeders in PXGL medium and then exchanged into N2B27 containing 2 μM XAV939 ([@bib22]). Chemical resetting was performed as described by [@bib8] with minor modifications. Somatic cell reprogramming was performed either with Sendai virus vectors ([@bib5]) or with episomal vectors (*pCXLE-OCT4-shRNA*(*p53*), *pCXLE-SOX2-KLF4*, and *pCXLE-L-MYC-LIN28* \[[@bib18]\]). For detailed procedures, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Human Embryo Culture and Staining {#sec4.3}
---------------------------------

Frozen embryos were thawed at day 5 or 6 post fertilization directly into N2B27 and cultured until fixation at day 7 post fertilization. Blastocysts were fixed in 4% PFA, immunostained, and imaged as described ([@bib30]).
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